Tendinopathy Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Novartis, ZARS Pharma Inc., Merck Sharp, Erasmus Medical Center, CTM Biomed

Posted on
by

Tendinopathy Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Novartis, ZARS Pharma Inc., Merck Sharp, Erasmus Medical Center, CTM Biomed
“Tendinopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Tendinopathy, historical and forecasted epidemiology as well as the Tendinopathy market trends in the 7MM.

DelveInsight’s “Tendinopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Tendinopathy, historical and forecasted epidemiology as well as the Tendinopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Tendinopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Tendinopathy Market Forecast

 

Some of the key facts of the Tendinopathy Market Report: 

  • The Tendinopathy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In November 2022, Camber Pharmaceuticals broadened its range of products by adding Naproxen Oral Suspension, prescribed for addressing the indications and manifestations of tendonitis.
  • In May 2022, CoNextions Inc., a company specializing in tendon repair, announced that the initial patient received treatment with the CoNextions TR Tendon Repair System for a zone 2 flexor tendon in the little finger just nineteen days after obtaining FDA 510(k) clearance for the device’s commercialization.
  • In the United States, specific to the type, there were approximately 4,856,800 cases of tendinitis and 7,285,200 cases of tendinosis. These figures are anticipated to rise by the year 2032.
  • In a research conducted by Muralidhara et al. (2022), it was found that the prevalence of Achilles tendinopathy in India is 7 cases per 100,000 individuals, with the highest occurrence observed within the age range of 20 to 60 years. Females exhibit a higher prevalence compared to males.
  • The number of reported cases of tendinopathy is increasing, with an approximate estimate of 12,142,000 cases in the United States in 2022.
  • In the United States in 2022, there were around 8,499,400 cases of tendinopathy reported, with 3,642,600 cases among males and females, respectively.
  • Key Tendinopathy Companies: Novartis, ZARS Pharma Inc., Merck Sharp, Erasmus Medical Center, CTM Biomedical, Zimmer Biomet, 3M, Teikoku Pharma USA Inc., DJO Global Inc., AKSIGEn, and others
  • Key Tendinopathy Therapies: secukinumab, NGI226, Heated Lidocaine and Tetracaine Patch, etoricoxib, PRP Injection with eccentric exercises, Celestone, and others
  • The Tendinopathy epidemiology based on gender analyzed that males are more affected by tendinopathy as compared to females
  • The Tendinopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tendinopathy pipeline products will significantly revolutionize the Tendinopathy market dynamics.

 

Tendinopathy Overview

Tendinopathy is a broad term used to describe conditions that involve damage, irritation, or inflammation of a tendon. Tendons are tough, fibrous tissues that connect muscles to bones, and they play a crucial role in the movement of joints. Tendinopathy can affect any tendon in the body, but it commonly occurs in areas like the shoulders, elbows, knees, and ankles.

 

Get a Free sample for the Tendinopathy Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/tendinopathy-market

 

Tendinopathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Tendinopathy Epidemiology Segmentation:

The Tendinopathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Tendinopathy
  • Prevalent Cases of Tendinopathy by severity
  • Gender-specific Prevalence of Tendinopathy
  • Diagnosed Cases of Episodic and Chronic Tendinopathy

 

Download the report to understand which factors are driving Tendinopathy epidemiology trends @ Tendinopathy Epidemiology Forecast

 

Tendinopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tendinopathy market or expected to get launched during the study period. The analysis covers Tendinopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Tendinopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Tendinopathy Therapies and Key Companies

  • secukinumab: Novartis
  • NGI226: Novartis
  • Heated Lidocaine and Tetracaine Patch: ZARS Pharma Inc.
  • etoricoxib: Merck Sharp
  • PRP Injection with eccentric exercises: Erasmus Medical Center
  • Celestone: CTM Biomedical

 

Discover more about therapies set to grab major Tendinopathy market share @ Tendinopathy Treatment Landscape

 

Tendinopathy Market Strengths

  • Preclinical models have given credence to this emerging therapeutic modality.
  • Compared to scaffolds and growth factors, there is a paucity of clinical studies using stem cells for augmentation of tendon repair or for treating tendinopathy.

 

Tendinopathy Market Opportunities

  • Gene Therapy is a promising method for facilitating the trafficking of growth factors to the injured site, potentially allowing sustained temporal delivery.
  • Novel mini-invasive procedures that target underlying pathology, such as abnormal neoinnervation, are being developed and are initially promising.

 

Scope of the Tendinopathy Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Tendinopathy Companies: Novartis, ZARS Pharma Inc., Merck Sharp, Erasmus Medical Center, CTM Biomedical, Zimmer Biomet, 3M, Teikoku Pharma USA Inc., DJO Global Inc., AKSIGEn, and others
  • Key Tendinopathy Therapies: secukinumab, NGI226, Heated Lidocaine and Tetracaine Patch, etoricoxib, PRP Injection with eccentric exercises, Celestone, and others
  • Tendinopathy Therapeutic Assessment: Tendinopathy current marketed and Tendinopathy emerging therapies
  • Tendinopathy Market Dynamics: Tendinopathy market drivers and Tendinopathy market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Tendinopathy Unmet Needs, KOL’s views, Analyst’s views, Tendinopathy Market Access and Reimbursement 

 

To know more about Tendinopathy companies working in the treatment market, visit @ Tendinopathy Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Tendinopathy Market Report Introduction

2. Executive Summary for Tendinopathy

3. SWOT analysis of Tendinopathy

4. Tendinopathy Patient Share (%) Overview at a Glance

5. Tendinopathy Market Overview at a Glance

6. Tendinopathy Disease Background and Overview

7. Tendinopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Tendinopathy 

9. Tendinopathy Current Treatment and Medical Practices

10. Tendinopathy Unmet Needs

11. Tendinopathy Emerging Therapies

12. Tendinopathy Market Outlook

13. Country-Wise Tendinopathy Market Analysis (2019–2032)

14. Tendinopathy Market Access and Reimbursement of Therapies

15. Tendinopathy Market Drivers

16. Tendinopathy Market Barriers

17.  Tendinopathy Appendix

18. Tendinopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services